Von Willebrand factor hyperactivity affects the outcome of lower limb revascularization in subjects with type 2 diabetes mellitus complicated by diabetic foot vasculopathy: An observational pilot study

J Diabetes Complications. 2024 Jan;38(1):108653. doi: 10.1016/j.jdiacomp.2023.108653. Epub 2023 Nov 25.

Abstract

Aim of this study is to evaluate any differences in VWF antigen, VWF activity and ADAMTS-13 activity before and after successful and non-successful Percutaneous Transluminal Angioplasty (PTA) in subjects with type 2 diabetes (T2DM) complicated by Chronic limb-threatening ischemia (CLTI) in diabetic foot vasculopathy.

Methods: In this prospective observational pilot study, we enrolled 35 T2DM subjects who underwent lower limb PTA. Transcutaneous oximetry was performed in all patients before and 6 weeks after PTA. The change in oxygen partial pressure (TcpO2) before and after PTA was expressed as TcpO2-delta (ΔTcpO2). VWF antigen, VWF activity and ADAMTS-13 activity were measured before and 6 weeks after PTA; changes were expressed as delta and ratio from baseline.

Results: Subjects with ∆TcpO2 < 15 mmHg presented higher ΔVWF activity (p = 0.050) and lower ADAMTS-13 activity ratio (p = 0.080). Subjects with ∆TcpO2 < 30 mmHg showed lower ADAMTS-13 activity Δ and ratio (p = 0.028).

Conclusions: VWF antigen levels and VWF activity may potentially affect PTA outcome. Higher levels of VWF could derive from VWF release as consequence of PTA-induced mechanical endothelial damage and/or oxidative stress-induced modifications of VWF structure with impairment of VWF-ADAMTS13 interactions.

Keywords: ADAMTS-13; Lower limb percutaneous transluminal angioplasty; Thrombotic angiopathies; Transcutaneous oximetry; Type 2 diabetes mellitus; Von Willebrand factor.

Publication types

  • Observational Study

MeSH terms

  • ADAMTS13 Protein
  • Diabetes Mellitus, Type 2* / complications
  • Diabetic Foot* / complications
  • Diabetic Foot* / surgery
  • Foot
  • Humans
  • Pilot Projects
  • Prospective Studies
  • von Willebrand Factor

Substances

  • von Willebrand Factor
  • ADAMTS13 Protein